PATENT CLAIM ANALYSIS

Application Number: 15939495
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["435", "006110"]

Abstract:
The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.

Claim (Index 1):
A method of treating or reducing the risk of a neurodegenerative disease in a human, the method comprising administering to said human an anti-PD-L1 antibody or antibody fragment that specifically binds to a human PD-L1 that is expressed by a PD-L1 nucleotide sequence comprising a variation selected from the group consisting of:\n rs1411262; rs4143815; 8923C; rs150439231; rs138261640; rs142983488; rs76741468; rs822336; rs183400620; rs187252832; rs146143976; rs139023765; rs73641615; rs17718883; rs139709512; rs140045210; rs141978642; rs146495642; rs370800260; rs143235887; rs373692552; rs140304675; rs12551333; rs376993991; rs367921713; rs41280721; rs61752860; rs148141792; rs369350813; rs10481593; rs2282055; rs2297135; rs2297136; rs2297137; rs3780395; rs7023227; rs1411262; rs34028061; rs7041009; rs148170925; rs10114060; rs1536926; and rs7042084; wherein the antibody or antibody fragment that specifically binds to human PD-L1 comprises:\n (i) a human gamma-1 heavy chain constant region that comprises an amino acid selected from the group consisting of: \n an Asp corresponding to position 204 of SEQ ID NO: 42 and a Leu corresponding to position 206 of SEQ ID NO: 42; or \n (ii) a human gamma-1 heavy chain constant region that comprises an amino acid selected from the group consisting of: \n an Glu corresponding to position 204 of SEQ ID NO: 42 and a Met corresponding to position 206 of SEQ ID NO: 42; or \n (iii) a human gamma-4 heavy chain constant region that comprises an amino acid selected from the group consisting of: \n a Leu corresponding to position 189 of SEQ ID NO: 73 and an Arg corresponding to position 289 of SEQ ID NO: 73; and \n wherein said human comprises:\n (iv) an IGHG1*01 human heavy chain constant region gene segment, or the human expresses antibodies comprising human gamma-1 heavy chain constant regions comprising said selected amino acid of clause (i), when the antibody or fragment is according to clause (i); or \n (v) an IGHG1*03 human heavy chain constant region gene segment, or the human expresses antibodies comprising human gamma-1 heavy chain constant regions comprising said selected amino acid of clause (ii)), when the antibody or fragment is according to clause (ii); or \n (vi) an IGHG4*01 human heavy chain constant region gene segment, or the human expresses antibodies comprising human gamma-4 heavy chain constant regions comprising said selected amino acid of clause (iii)), when the antibody or fragment is according to clause (iii); and \n wherein said human comprises:\n (vii) a PD-L1 nucleotide sequence comprising said selected variation.

Metadata:
- Claim Count in Document: 4.0
- Percentile: 90.0
- Lexical Diversity: 1.05263
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14536049', '14659910', '15939503', '14731727', '14868952']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7439982150089552
- 35 USC 102 Novelty (BERT): 0.6860197193380767
- Combined Prediction Score: 0.7382003654418674
- Mean Citation Score: 783.1729640000003
- Max Citation Score: 795.2167400000003
- Similarity Product: 710.7594770437539

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test